Search Results

You are looking at 21 - 30 of 388 items for :

  • Refine by Access: All x
Clear All
Full access

EPR19-73: Risk of Gastrointestinal and Hepatic Toxicities in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors

Anita Sultan, Sriman Swarup, Somedeb Ball, Miguel Quirch, Meily Arevalo, Yin M. Myat, Ye Aung, Myo H. Zaw, and Kyaw Z. Thein

placebo in combination with letrozole or anastrozole or fulvestrant or other hormonal agents. The RR of all-grade side effects were as follows: diarrhea, 1.691 (95% CI: 1.220–2.345; P =.002); nausea, 1.632 (95% CI: 1.447–1.840; P <.001); vomiting, 1

Full access

Antiemetic Studies on the NK1 Receptor Antagonist Aprepitant

John P. Stoutenburg and Harry Raftopoulos

comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting . Eur J Cancer 1997 ; 33 : 66 – 74 . 2 Grunberg SM Hansen M Deuson R : Incidence and impact of nausea/vomiting with

Full access

Edmonton Symptom Assessment Scale and Clinical Characteristics Associated With Cannabinoid Use in Oncology Supportive Care Outpatients

Young D. Chang, Jae-Woo Jung, Ritika Oberoi-Jassal, Jongphil Kim, Sahana Rajasekhara, Meghan Haas, Joshua Smith, Vijay Desai, Kristine A. Donovan, and Diane Portman

, including chronic pain, spasticity, seizures, anorexia, nausea, and glaucoma. 2 – 4 In addition, marijuana has been highlighted as a potential immune-modulating or anticancer agent. 5 Given the symptom burden reported by patients in the oncology outpatient

Full access

Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy

Ciara C. O'Sullivan, Holly K. Van Houten, Lindsey R. Sangaralingham, Alexis D. Leal, Shivani Shinde, Hongfang Liu, David Ettinger, Charles L. Loprinzi, and Kathryn J. Ruddy

Chemotherapy-induced nausea and vomiting (CINV) is common during cancer treatment due to a complex multifactorial process involving several different pathways and transmitters. Highly emetogenic chemotherapy (HEC) regimens are associated with >90

Full access

What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy

Eric J. Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Ryan D. Nipp, Gary Binder, Silvia Sebastiani, Ravi Potluri, Luke Schmerold, Eros Papademetriou, Lee Schwartzberg, and Rudolph M. Navari

Background Despite the availability of evidence-based guidelines for the prevention of chemotherapy-induced nausea and vomiting (CINV), adherence to these guidelines remains suboptimal. In addition to the impact on quality of life (QoL), poorly

Full access

Complications of Radioactive Iodine Treatment of Thyroid Carcinoma

Stephanie L. Lee

-term alterations in taste have been reported. Gastrointestinal Complications Nausea is the most common gastrointestinal symptom of RAI therapy but is rarely accompanied by emesis. 5 Studies have shown that 50% to 67% of patients complain of nausea

Full access

QIM19-130: Quality Improvement Project to Standardize a Prehabilitation Pathway for Patients With Esophageal Cancer Receiving Neoadjuvant Chemoradiation

Ashley E. Glode, S. Lindsey Davis, Supriya K. Jain, Megan D. Marsh, Lisa J. Wingrove, Tracey E. Schefter, Karyn Goodman, Lindel C.K. Dewberry, Martin D. McCarter, Laura Melton, Michelle Bunch, William T. Purcell, and Stephen Leong

treatments, with an average relative dose intensity of 111.4% for carboplatin and 112.9% for paclitaxel. In the pre-STRENGTH group, one patient did not complete their planned radiation dose due to nausea, vomiting, and dehydration. All patients in the

Full access

Adherence to the World Cancer Research Fund/American Institute for Cancer Research Guideline Is Associated With Better Health-Related Quality of Life Among Chinese Patients With Breast Cancer

Yuan-Yuan Lei, Suzanne C. Ho, Ashley Cheng, Carol Kwok, Chi-Kiu Iris Lee, Ka Li Cheung, Roselle Lee, Herbert H.F. Loong, Yi-Qian He, and Winnie Yeo

-specific HRQoL issues relevant to a broad spectrum of patients with cancer. 30 The QLQ-C30 included a global health and QoL domain, 5 functional domains (physical, role, emotional, cognitive, and social), 3 symptom domains (fatigue, nausea and vomiting, and pain

Full access


Fox Chase Cancer Center

Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory.

For the most recent version of the guidelines, please visit

Full access

HSR19-091: Incidence of Adverse Events Following Use of Different PARP Inhibitors: Systematic Review and Meta-Analysis

Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad, and Andrea Wahner Hendrickson

). Of 1,685 patients who received PARPi, incidence of any AE, regardless of grade, was 98.5% (95% CI, 97.2–99.2%). Common AEs were: nausea (incidence rate, 68.9% and 95% CI, 58.7%–77.5%), fatigue (56.3%, 45.3%–66.8%), anemia (46.3%, 37